Viewing Study NCT05285904

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:14 PM
Ignite Modification Date: 2026-01-25 @ 3:44 AM
Study NCT ID: NCT05285904
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-01
First Post: 2022-03-08
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Multiple Sclerosis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None NIS View
None Multiple sclerosis View
None MS View
None KOSMOS View
None Ofatumumab View
None Kesimpta View